Omaveloxolone (Skyclarys): Indication: For the treatment of Friedreich’s ataxia in patients 16 years of age and older: Reimbursement Recommendation [Internet]

Omaveloxolone (Skyclarys): Indication: For the treatment of Friedreich’s ataxia in patients 16 years of age and older: Reimbursement Recommendation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Jul. Report No.: SR0864. PMID: 40857368.

What Is the Reimbursement Recommendation for Skyclarys?: Canada’s Drug Agency (CDA-AMC) recommends that Skyclarys be reimbursed by public drug plans for the treatment of Friedreich’s ataxia (FA) if certain conditions are met.

Omaveloxolone (Skyclarys): Indication: For the treatment of Friedreich’s ataxia in patients 16 years of age and older: Reimbursement Recommendation [Internet]